BAY 2862789 — Investigational Agent
Other · Phase 1 · Bayer
Mechanism of Action
Oral diacylglycerol kinase alpha (DGKalpha) inhibitor that augments T-cell activation by sustaining diacylglycerol-driven signaling downstream of the T-cell receptor. Functions as an intracellular immune checkpoint inhibitor to enhance anti-tumor immunity.
Investigational Indications
- Advanced solid tumors
- Non-small cell lung cancer